Skip to main content

Advertisement

Table 2 Details of the clinical, biological and treatment data collected during each follow-up visit

From: Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study

  Month 0 Month 3 Month 6 Month 12
Patients attending the visit 78 (100%) 42 (65.6%) 54 (84.4%) 38 (59.4%)
Serum urate (mg/dL) 7.43 ± 2.33 6.57 ± 1.9 5.59 ± 1.56 5.63 ± 1.81
Ongoing ULT 36 (46.2%) 33 (78.5%) 47 (87.1%) 34 (89.4%)
Ongoing flare prophylaxis 25 (32.1%) 20 (47.6%) 27 (50%) 16 (42.1%)
Number of flares since M0 N/A 0.6 ± 1.3 0.7 ± 1.4 1.5 ± 3.3
Patients with at least 1 flare since M0 N/A 15 (35.7%) 19 (35.2%) 16 (42.1%)
Number of flares since previous visit N/A 0.6 ± 1.3 0.3 ± 0.7 0.7 ± 1.6
Patients with at least 1 flare since previous visit N/A 15 (35.7%) 9 (17%) 12 (31.6%)
  1. M0 month 0, ULT urate lowering therapy